Xeloda (capecitabine) is an orally-administered chemotherapy drug approved by the U.S. Food and Drug Administration for patients with advanced-stage breast cancer or colorectal cancer. Studies have shown that the drug can improve the quality of life for patients facing the late stages of these cancers.Forbes.com: Chemotherapy Superior to New Drug for Early Breast Cancer (May 12, 2009)
According to oncologist Eng-Huat Tan, the drug can cause hand-foot syndrome, which over time can erase the fingerprints of one using the medication. A 62-year-old long-time user of the drug was initially denied entry to the United States after his fingerprints could not be read by customs officials. The man has since changed medications and carries a doctor's note when traveling internationally.CNN: Cancer Drug Erases Man's Fingerprints, Doctor Says
Use for Breast Cancer
In May 2009, a University of Vermont study indicated that Xeloda was less beneficial for early-stage breast cancer patients that traditional chemotherapy.Forbes.com: Chemotherapy Superior to New Drug for Early Breast Cancer (May 12, 2009) When treated with Xeloda alone, older patients with early stage breast cancer had twice the rate of relapse and death than those given standard chemotherapy.Reuters: Early Xeloda does not help in breast cancer (May 12, 2009)
Disclaimer
The content in this page is not a substitute for professional medical advice. If you think you have cancer, please consult your doctor.
References
Fast Facts
-
Manufacturer
Roche Laboratories, Inc.
-
Fact:
-
Fact:
Available by prescription only
-
Active ingredient
Capecitabine
-
Strengths
150mg and 500mg
-
Form
Tablets
-
Uses
Advanced-stage treatment of colorectal and breast cancersFDA.gov: Xeloda Patient Information Sheet
-
Fact:
-
Fact:
May increase lifespan when used in combination with certain other chemotherapy drugsFDA.gov: Xeloda Patient Information Sheet
-
Fact:
First orally administered chemotherapy drug approved by FDA
